RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
THE BAJA POSTNEWSROOMSOURCE: https://prnmedia.prnewswire.com/ The global Phase 2/3 study of orally-administered opaganib for the treatment of severe COVID-19 enrolled a total of 475 patients, more … Sigue leyendo RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
Copia y pega esta URL en tu sitio WordPress para incrustarlo
Copia y pega este código en tu sitio para incrustarlo